Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003047594 | SCV003342946 | pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2022-04-16 | criteria provided, single submitter | clinical testing | This variant, c.493_531del, results in the deletion of 13 amino acid(s) of the GALNS protein (p.Cys165_Asn177del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with GALNS-related conditions. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts a region of the GALNS protein in which other variant(s) (p.Gly168Arg) have been determined to be pathogenic (PMID: 9298823, 29275451, 30927141; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |